Denali Therapeutics Inc (FRA:4DN)
€ 20.31 -0.18 (-0.88%) Market Cap: 2.85 Bil Enterprise Value: 2.09 Bil PE Ratio: 0 PB Ratio: 2.25 GF Score: 54/100

Passage Bio Inc, Denali Therapeutics, and Prevail Therapeutics at Citi BioPharma Conference (Virtual) - Panel Transcript

Sep 10, 2020 / 07:20PM GMT
Release Date Price: €27.6 (+4.94%)
Neena Marie Bitritto;Garg;Asa Abeliovich
Citigroup Inc., Research Division - VP & Analyst;Prevail Therapeutics Inc. - Founder, President, CEO

All right. Hi, everyone. Thank you so much for joining the Citi's 15th Annual Biopharma Conference. My name is Neena Bitritto-Garg. I'm one of the mid-cap biotech analyst here at Citi.

So for our next panel, I'm very pleased to be joined by CEOs from Denali, Passage Bio and Prevail Therapeutics. So from Denali, we have Ryan Watts. From Passage Bio, we have Bruce Goldsmith. And from Prevail, we have Asa -- sorry, I apologize, Abeliovich. And we're going talk today about neurodegenerative diseases and some of the emerging and new kind of therapeutic modalities and mechanisms that companies are working on to combat neurodegenerative disease.

So to start off, I'd like to give everyone the opportunity to kind of just give a quick 1-minute intro kind of on the company, on -- and what you're working on right now. So if we want to start with -- maybe with Asa, and then we can go to Bruce and then Ryan.

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot